Ichnos Cyril Konto, President & CEO of Ichnos Sciences comments on the company’s unique approach to finding new cancer treatments, the possibility of becoming fully independent from parent company Glenmark Pharmaceuticals and the licensing agreement Ichos has with Almirall for the IL-1RAP antagonist, ISB 880. … the Ichnos team has further…
See our Cookie Privacy Policy Here